Interferon beta-1a vs. glatiramer acetate: changes of innate
immunity in a group of women with multiple sclerosis

J 2023

Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis

PETERKA, Marek, Martin VALIS, Ondrej SOUCEK, Jan KREJSEK, Lukas SOBISEK et. al.

Basic information

Original name

Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis

Authors

PETERKA, Marek (203 Czech Republic), Martin VALIS (203 Czech Republic), Ondrej SOUCEK (203 Czech Republic), Jan KREJSEK (203 Czech Republic), Lukas SOBISEK (203 Czech Republic), Ilona SEJKOROVA (203 Czech Republic), Blanka KLIMOVA (203 Czech Republic), Pavel ŠTOURAČ (203 Czech Republic, belonging to the institution), Zbysek PAVELEK (203 Czech Republic) and Michal NOVOTNY (203 Czech Republic)

Edition

EUROPEAN NEUROLOGY, BASEL, KARGER, 2023, 0014-3022

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30210 Clinical neurology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.400 in 2022

RIV identification code

RIV/00216224:14110/23:00133490

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1159/000532022

UT WoS

001036985900001

Keywords in English

Multiple Sclerosis; Interferon Beta-1a; Glatiramer Acetate

Abstract

V originále

Introduction: Multiple sclerosis is a chronic inflammatory autoimmune demyelinating disease that secondarily leads to the axonal loss and associated brain atrophy. Disease-modifying drugs (DMDs) have previously been studied for their ability to affect specific immunity. This study investigates the effect of interferon beta-1a (INF) and glatiramer acetate (GA) administration on changes in innate immunity cell populations. Methods: Sixty Caucasian female patients with relapsing-remitting multiple sclerosis undergo blood sample testing for 15 blood parameters at baseline, 1M, 3M and 6M after treatment by GA or IFN (started as their first line DMD). Results: A statistically significant difference in the change after 6 months was found in the parameter monocytes (relative count) in the group of patients treated with IFN. The median increase was 27.8%. Changes in many of the other 15 parameters studied were 10-20%. Conclusion: Innate immunity has long been neglected in MS immunopathology. The findings of this study show that innate immunity cells, especially monocytes may contribute significantly to MS immunopathology.

Citovat

PETERKA, Marek, Martin VALIS, Ondrej SOUCEK, Jan KREJSEK, Lukas SOBISEK, Ilona SEJKOROVA, Blanka KLIMOVA, Pavel ŠTOURAČ, Zbysek PAVELEK and Michal NOVOTNY. Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis. EUROPEAN NEUROLOGY. BASEL: KARGER, 2023, vol. 86, No 5, p. 334-340, 14 pp. ISSN 0014-3022. Available from: https://dx.doi.org/10.1159/000532022.

@article{2371617,
   author = {Peterka, Marek and Valis, Martin and Soucek, Ondrej and Krejsek, Jan and Sobisek, Lukas and Sejkorova, Ilona and Klimova, Blanka and Štourač, Pavel and Pavelek, Zbysek and Novotny, Michal},
   article_location = {BASEL},
   article_number = {5},
   doi = {http://dx.doi.org/10.1159/000532022},
   keywords = {Multiple Sclerosis; Interferon Beta-1a; Glatiramer Acetate},
   language = {eng},
   issn = {0014-3022},
   journal = {EUROPEAN NEUROLOGY},
   title = {Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis},
   url = {https://karger.com/ene/article/86/5/334/860198/Interferon-Beta-1a-versus-Glatiramer-Acetate},
   volume = {86},
   year = {2023}
}

TY  - JOUR
ID  - 2371617
AU  - Peterka, Marek - Valis, Martin - Soucek, Ondrej - Krejsek, Jan - Sobisek, Lukas - Sejkorova, Ilona - Klimova, Blanka - Štourač, Pavel - Pavelek, Zbysek - Novotny, Michal
PY  - 2023
TI  - Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis
JF  - EUROPEAN NEUROLOGY
VL  - 86
IS  - 5
SP  - 334-340
EP  - 334-340
PB  - KARGER
SN  - 00143022
KW  - Multiple Sclerosis
KW  - Interferon Beta-1a
KW  - Glatiramer Acetate
UR  - https://karger.com/ene/article/86/5/334/860198/Interferon-Beta-1a-versus-Glatiramer-Acetate
N2  - Introduction: Multiple sclerosis is a chronic inflammatory autoimmune demyelinating disease that secondarily leads to the axonal loss and associated brain atrophy. Disease-modifying drugs (DMDs) have previously been studied for their ability to affect specific immunity. This study investigates the effect of interferon beta-1a (INF) and glatiramer acetate (GA) administration on changes in innate immunity cell populations. Methods: Sixty Caucasian female patients with relapsing-remitting multiple sclerosis undergo blood sample testing for 15 blood parameters at baseline, 1M, 3M and 6M after treatment by GA or IFN (started as their first line DMD). Results: A statistically significant difference in the change after 6 months was found in the parameter monocytes (relative count) in the group of patients treated with IFN. The median increase was 27.8%. Changes in many of the other 15 parameters studied were 10-20%. Conclusion: Innate immunity has long been neglected in MS immunopathology. The findings of this study show that innate immunity cells, especially monocytes may contribute significantly to MS immunopathology.
ER  -

PETERKA, Marek, Martin VALIS, Ondrej SOUCEK, Jan KREJSEK, Lukas SOBISEK, Ilona SEJKOROVA, Blanka KLIMOVA, Pavel ŠTOURAČ, Zbysek PAVELEK and Michal NOVOTNY. Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis. \textit{EUROPEAN NEUROLOGY}. BASEL: KARGER, 2023, vol.~86, No~5, p.~334-340, 14 pp. ISSN~0014-3022. Available from: https://dx.doi.org/10.1159/000532022.

Detailed Information on Publication Record